The effect of salinomycin on ovarian cancer stem-like cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThe identification of cancer stem-like cells is a recent development in ovarian cancer. Compared to other cancer cells, cancer stem-like cells present more chemo-resistance and more aggressive characteristics. They play an important role in the recurrence and drug resistance of cancer. Therefore, the target therapy of cancer stem-like cell may become a promising and effective approach for ovarian cancer treatment. It may also help to provide novel diagnostic and therapeutic strategies. MethodsThe OVCAR3 cell line was cultured under serum-free conditions to produce floating spheres. The CD44+CD117+ cell line was isolated from the human ovarian cancer cell line OVCAR3 by using immune magnetic-activated cell sorting system. The expression of stemness genes such as OCT3/4, NANOG and SOX2 mRNA were determined by reverse transcription polymerase chain reaction. OVCAR3 parental and OVCAR3 CD44+CD117+ cells were grown in different doses of paclitaxel and salinomycin to evaluate the effect of salinomycin. And growth inhibition of OVCAR3 CD44+CD117+ cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. ResultsTumor spheroids generated from the OVCAR3 cell line are shown to have highly enriched CD44 and CD117 expression. Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44+CD117+ cells. ConclusionThe present study is a detailed investigation on the expression of CD44 and CD117 in cancer stem cells and evaluates their specific tumorigenic characteristics in ovarian cancer. This study also demonstrates significant growth inhibition of cancer stem-like cells by paclitaxel combined with salinomycin. Identification of these cancer stem-like cell markers and growth inhibition effect of salinomycin may be the next step to the development of novel target therapy in ovarian cancer.
Abstract
ObjectiveThe identification of cancer stem-like cells is a recent development in ovarian cancer. Compared to other cancer cells, cancer stem-like cells present more chemo-resistance and more aggressive characteristics. They play an important role in the recurrence and drug resistance of cancer. Therefore, the target therapy of cancer stem-like cell may become a promising and effective approach for ovarian cancer treatment. It may also help to provide novel diagnostic and therapeutic strategies. MethodsThe OVCAR3 cell line was cultured under serum-free conditions to produce floating spheres. The CD44+CD117+ cell line was isolated from the human ovarian cancer cell line OVCAR3 by using immune magnetic-activated cell sorting system. The expression of stemness genes such as OCT3/4, NANOG and SOX2 mRNA were determined by reverse transcription polymerase chain reaction. OVCAR3 parental and OVCAR3 CD44+CD117+ cells were grown in different doses of paclitaxel and salinomycin to evaluate the effect of salinomycin. And growth inhibition of OVCAR3 CD44+CD117+ cells by paclitaxel combined with salinomycin was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. ResultsTumor spheroids generated from the OVCAR3 cell line are shown to have highly enriched CD44 and CD117 expression. Treatment with a combination of paclitaxel and salinomycin demonstrated growth inhibition of OVCAR3 CD44+CD117+ cells. ConclusionThe present study is a detailed investigation on the expression of CD44 and CD117 in cancer stem cells and evaluates their specific tumorigenic characteristics in ovarian cancer. This study also demonstrates significant growth inhibition of cancer stem-like cells by paclitaxel combined with salinomycin. Identification of these cancer stem-like cell markers and growth inhibition effect of salinomycin may be the next step to the development of novel target therapy in ovarian cancer.
참고문헌 (24)
- Ozols RF, "Treatment goals in ovarian cancer", Int J Gynecol Cancer, 15(Suppl 1), pp.3~11 (2005)
- Banerjee S, "New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential", Clin Cancer Res, 19, pp.961~968 (2013)
- Foster R, "Ovarian cancer stem cells: working towards the root of stemness", Cancer Lett, 338, pp.147~157 (2013)
- Ahmed N, "Cancerous ovarian stem cells : obscure targets for therapy but relevant to chemoresistance", J Cell Biochem, 114, pp.21~34 (2013)
- Zhan Q, "Ovarian cancer stem cells : a new target for cancer therapy", Biomed Res Int, 2013, pp.916819~ (2013)
- Loh YH, "The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells", Nat Genet, 38, pp.431~440 (2006)
- Mitani M, "Salinomycin : a new monovalent cation ionophore", Biochem Biophys Res Commun, 66, pp.1231~1236 (1975)
- Gupta PB, "Identification of selective inhibitors of cancer stem cells by high-throughput screening", Cell, 138, pp.645~659 (2009)
- Resham K, "Preclinical drug metabolism and pharmacokinetics of salinomycin, a potential candidate for targeting human cancer stem cells", Chem Biol Interact, 240, pp.146~152 (2015)
- Chen J, "Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures", BMC Cell Biol, 14, pp.7~ (2013)
- Jayson GC, "Ovarian cancer", Lancet, 384, pp.1376~1388 (2014)
- Hermann PC, "Metastatic cancer stem cells: a new target for anti-cancer therapy?", Cell Cycle, 7, pp.188~193 (2008)
- Dean M, "Tumour stem cells and drug resistance", Nat Rev Cancer, 5, pp.275~284 (2005)
- Clarke MF, "Cancer stem cells : perspectives on current status and future directions : AACR Workshop on cancer stem cells", Cancer Res, 66, pp.9339~9344 (2006)
- Shi MF, "Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line", Cell Mol Life Sci, 67, pp.3915~3925 (2010)
- Zhang S, "Identification and characterization of ovarian cancer-initiating cells from primary human tumors", Cancer Res, 68, pp.4311~4320 (2008)
- Bapat SA, "Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer", Cancer Res, 65, pp.3025~3029 (2005)
- Burgos-Ojeda D, "Ovarian cancer stem cell markers : prognostic and therapeutic implications", Cancer Lett, 322, pp.1~7 (2012)
- Alvero AB, "Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance", Cell Cycle, 8, pp.158~166 (2009)
- Luo L, "Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome", Exp Mol Pathol, 91, pp.596~602 (2011)
- Naujokat C, "Salinomycin as a drug for targeting human cancer stem cells", J Biomed Biotechnol, 2012, pp.950658~ (2012)
- Miyazaki Y, "Salinomycin, a new polyether antibiotic", J Antibiot (Tokyo), 27, pp.814~821 (1974)
- An H, "Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway", Biochem Biophys Res Commun, 466, pp.696~703 (2015)
- Qu H, "Effect of salinomycin on metastasis and invasion of bladder cancer cell line T24", Asian Pac J Trop Med, 8, pp.578~582 (2015)